Hiroki Shimada

Hiroki Shimada

Auto-generated profile, based on publicly available information

Hiroki Shimada

Department of Pharmacoepidemiology Graduate School of Medicine and Public Health, Kyoto University Kyoto Japan

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2019 in CEN Case Reports
Verified
Journal Article
Closed access
PDF file
MIMasaki Ikeda
Masaki Ikeda
MTMari Tanaka
Mari Tanaka
SSSaeko Shimoda
Saeko Shimoda
HSHirona Saita
Hirona Saita
SNSeira Nishikawa
Seira Nishikawa
HTHiroya Takeoka
Hiroya Takeoka

15 October 2019 in Internal Medicine
Verified
Journal Article
Open access
PDF file
MTMari Tanaka
Mari Tanaka
SMSho Miki
Sho Miki
HSHirona Saita
Hirona Saita
HSHiroki Shimada
Hiroki Shimada
SNSeira Nishikawa
Seira Nishikawa
HTHiroya Takeoka
Hiroya Takeoka
MYH9-related disease is a rare genetic disorder characterized by macrothrombocytopenia, with frequent proteinuric nephropathy, hearing loss, and cataract. Although proteinuric nephropathy usually progresses to renal failure, there is no established treatment for the nephropathy. We herein describe the case of a 19-year-old man carrying an E1841K MYH9 mutation, who developed persistent proteinuria. The patient was diagnosed with early-stage MYH9-related nephropathy based on the histological examination of a kidney biopsy specimen. The patient was treated with enalapril, which significantly reduced the proteinuria with no decline in his renal function. The early administration of renin-angiotensin system blockade therapy may have beneficial effects on MYH9-related nephropathy in patients with E1841K mutations. We also briefly summarize previously published cases of MYH9-related nephropathy treated with RAS blockade therapy.

10 May 2019 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Open access
PDF file
SMSho Miki
Sho Miki
Yasushi TsujimotoYasushi Tsujimoto
Yasushi Tsujimoto
HSHiroki Shimada
Hiroki Shimada
HTHiraku Tsujimoto
Hiraku Tsujimoto
HYHideto Yasuda
Hideto Yasuda
TFTomoko Fujii
Tomoko Fujii
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: This review will aim to assess the efficacy, safety, and effectiveness of non‐pharmacological measures to maintain circuit patency in CRRT.

5 March 2020 in Renal Replacement Therapy
Verified
Journal Article
Open access
PDF file
HSHiroki Shimada
Hiroki Shimada
MTMari Tanaka
Mari Tanaka
YTYohtaro Takami
Yohtaro Takami
MTMariko Teragaki
Mariko Teragaki
KMKotaro Maeda
Kotaro Maeda
HTHiroya Takeoka
Hiroya Takeoka
Septic pulmonary embolism (SPE) is an uncommon but serious complication resulting from infection of the blood. Gram-positive cocci, including methicillin-susceptible Staphylococcus aureus and methicillin-resistant Staphylococcus aureus, are the most common causative organisms of SPE. Few case reports have been published on SPE caused by Pseudomonas aeruginosa (P. aeruginosa), and thus, the consensus treatment of SPE caused by P. aeruginosa infections remains undetermined. Management of P. aeruginosa infection can be challenging due to its poor prognosis and antimicrobial resistance. Here, we report a case of successful combination antibiotic therapy for SPE associated with infective endocarditis (IE) caused by P. aeruginosa in a hemodialysis patient, with a review of the literature. A 62-year-old man receiving maintenance hemodialysis as treatment for end-stage renal disease due to IgA nephropathy was admitted to our hospital with high fever and chills lasting 10 days. Chest computed tomography revealed multiple nodular shadows, and gram-negative rods were confirmed by blood culture obtained on admission. We suspected SPE and initiated meropenem (MEPM) treatment. P. aeruginosa was identified in blood cultures, and transesophageal echocardiography demonstrated vegetation on the tricuspid valve. Therefore, a diagnosis of SPE associated with IE caused by P. aeruginosa was made. P. aeruginosa isolates showed good susceptibility to MEPM, but no symptomatic improvement was observed. Thus, antibiotics were changed from MEPM to a combination of ceftazidime and tobramycin (TOB). The patient exhibited a favorable response to the combination therapy, although we discontinued TOB on day 23 because of tinnitus symptoms. We report a rare case of SPE associated with IE caused by P. aeruginosa in a hemodialysis patient. Combination antibiotic therapy may be effective in this situation.

20 November 2023 in Therapeutic Apheresis and Dialysis
Verified
Journal Article
Closed access
HSHiroki Shimada
Hiroki Shimada
YMYoshinori Matsuoka
Yoshinori Matsuoka
CMChisato Miyakoshi
Chisato Miyakoshi
JIJiro Ito
Jiro Ito
RSRyutaro Seo
Ryutaro Seo
HMHiroyuki Mima
Hiroyuki Mima

19 March 2026 in Therapeutic Apheresis and Dialysis
Verified
Journal Article
Closed access
KKKano Ken-ichi
Kano Ken-ichi
KMKayoko Mizuno
Kayoko Mizuno
HSHiroki Shimada
Hiroki Shimada
CTChikashi Takeda
Chikashi Takeda
KKKoji Kawakami
Koji Kawakami